{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:12:04Z","timestamp":1774577524250,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1498,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1111\/j.1600-0609.2011.01654.x","type":"journal-article","created":{"date-parts":[[2011,5,30]],"date-time":"2011-05-30T12:57:40Z","timestamp":1306760260000},"page":"244-252","source":"Crossref","is-referenced-by-count":59,"title":["Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of \u2265120\u2003g\/L with darbepoetin alfa\u2003\u00b1\u2003filgrastim or erythrocyte transfusions"],"prefix":"10.1111","volume":"87","author":[{"given":"Herman","family":"Nilsson-Ehle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Birgeg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Samuelsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petar","family":"Antunovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Astermark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hege","family":"Garelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena M.","family":"Engstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Skov-Holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Wallvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Gulbrandsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Hellstr\u00f6m-Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB2|cit2","author":"World Health Organization","year":"1968","journal-title":"In WHO Techn Rep"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB3|cit3","first-page":"1286","article-title":"Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology","volume":"87","author":"Alessandrino","year":"2002","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB4|cit4","unstructured":"Kjeldsen L Dybedal I Garelius H Juvonen E Nilsson L Reykdal S Skov Holm M Garelius H Hellstr\u00f6m Lindberg E Treatment with EPO\/darbepoetin alone or in combination with G-CSF for the anemia of MDS Nordic MDS Group 2010 19 21"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"902","DOI":"10.6004\/jnccn.2008.0069","article-title":"Myelodysplastic syndromes","volume":"6","author":"Greenberg","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin\u2003+\u2003granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstr\u00f6m-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood-2004-10-3872","article-title":"Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF","volume":"106","author":"J\u00e4dersten","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2007.15.4906","article-title":"Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome","volume":"26","author":"J\u00e4dersten","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.22343","article-title":"Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes","volume":"107","author":"Giraldo","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2006.06070.x","article-title":"High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study","volume":"133","author":"Mannone","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2141.2008.07181.x","article-title":"Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes","volume":"142","author":"Gabrilove","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00277-008-0450-7","article-title":"Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis","volume":"87","author":"Moyo","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3109\/10428191003728610","article-title":"Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life","volume":"51","author":"Oliva","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00277-005-1060-2","article-title":"Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim","volume":"84","author":"Jakob","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.20725","article-title":"Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor","volume":"82","author":"Rose","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajh.21316","article-title":"A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes","volume":"84","author":"Gotlib","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2141.2003.04272.x","article-title":"Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes","volume":"121","author":"Jansen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.0902-4441.2003.00183.x","article-title":"Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report","volume":"72","author":"Clavio","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00277-004-0961-9","article-title":"Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome","volume":"84","author":"Spiriti","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00277-005-0044-6","article-title":"Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study","volume":"85","author":"Balleari","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2003-07-2252","article-title":"Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial","volume":"104","author":"Casadevall","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1532-5415.2004.52208.x","article-title":"Anemia is associated with disability and decreased physical performance and muscle strength in the elderly","volume":"52","author":"Penninx","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1532-5415.2005.00491.x","article-title":"Late-life anemia is associated with increased risk of recurrent falls","volume":"53","author":"Penninx","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","article-title":"Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload","volume":"22","author":"Anderson","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2141.2007.06695.x","article-title":"Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions","volume":"138","author":"Chacko","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ajh.20980","article-title":"No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique","volume":"82","author":"Konen","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2008.10.018","article-title":"Evaluation of cardiac iron overload in transfusion-dependent adult marrow failure patients by magnetic resonance imaging","volume":"33","author":"Park","year":"2009","journal-title":"Leuk Res"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB29|cit29","first-page":"61","volume-title":"World Health Organization Classification of Tumors Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue","author":"Brunning","year":"2003"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.CIR.64.6.1227","article-title":"Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale","volume":"64","author":"Goldman","year":"1981","journal-title":"Circulation"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","article-title":"Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients","volume":"92","author":"Hellstrom-Lindberg","year":"1998","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies","volume":"89","author":"Hellstr\u00f6m-Lindberg","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2141.1996.d01-1802.x","article-title":"Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone\u2003+\u2003alpha-interferon. The Nordic Myeloma Study Group","volume":"94","author":"Wisloff","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO.1995.13.5.1249","article-title":"Test\/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire","volume":"13","author":"Hjermstad","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","article-title":"Survival and causes of death in thalassaemia major","volume":"2","author":"Zurlo","year":"1989","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.21269","article-title":"Consensus statement on iron overload in myelodysplastic syndromes","volume":"83","author":"Bennett","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1600-0609.2011.01654.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12185-008-0118-z","article-title":"Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload","volume":"88","author":"Gattermann","year":"2008","journal-title":"Int J Hematol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01654.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2011.01654.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T06:19:32Z","timestamp":1625638772000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01654.x"}},"subtitle":["Quality of life improves in MDS patients treated for anaemia"],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01654.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,26]]}}}